Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Rybowski

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Clinical Breast Cancer|March 8, 2021
Development of a Prognostic Factor Index Among Women With HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast Cancer in a Community Oncology SettingGregory A Vidal, Gebra Cuyun Carter, Adrienne M Gilligan, et al.
Current Medical Research and Opinion|May 10, 2022
Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community settingGregory L Price, Lavanya Sudharshan, Paula Ryan, et al.
Current Medical Research and Opinion|May 10, 2021
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancerGebra Cuyun Carter, Kristin M Sheffield, Anala Gossai, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Clinical Breast Cancer|March 8, 2021
Development of a Prognostic Factor Index Among Women With HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast Cancer in a Community Oncology SettingGregory A Vidal, Gebra Cuyun Carter, Adrienne M Gilligan, et al.
Current Medical Research and Opinion|May 10, 2022
Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community settingGregory L Price, Lavanya Sudharshan, Paula Ryan, et al.
Current Medical Research and Opinion|May 10, 2021
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancerGebra Cuyun Carter, Kristin M Sheffield, Anala Gossai, et al.
Pageof 2